HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth

HEC Pharma’s revenue jumped ~6x in 1H22, driven by volume recovery of its core drug Kewei. Going ahead, new generic launches and insulin portfolio should accelerate the company’s growth trajectory.

SUMMARY

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

• Unlimited Research Summaries
• Personalised Alerts
• Custom Watchlists
• Company Data & News
• Events & Webinars

Trusted by:

SMARTKARMA PREVIEW PASS

Sign Up with LinkedIn

or

First NameLast nameEmail

Sign Up with EmailBy signing up, you agree to our
Terms of Use and Privacy Policy.

Trusted by:

Already have an account? Sign In Now

---